EA201071183A1 - Безводная кристаллическая форма малеата орвепитанта - Google Patents

Безводная кристаллическая форма малеата орвепитанта

Info

Publication number
EA201071183A1
EA201071183A1 EA201071183A EA201071183A EA201071183A1 EA 201071183 A1 EA201071183 A1 EA 201071183A1 EA 201071183 A EA201071183 A EA 201071183A EA 201071183 A EA201071183 A EA 201071183A EA 201071183 A1 EA201071183 A1 EA 201071183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
orpetita
crystal form
free crystal
form male
crystalline form
Prior art date
Application number
EA201071183A
Other languages
English (en)
Other versions
EA017082B1 (ru
Inventor
Стефания Беато
Франко Сартор
Ян Филип Стиплз
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201071183A1 publication Critical patent/EA201071183A1/ru
Publication of EA017082B1 publication Critical patent/EA017082B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается безводной кристаллической формы малеата орвепитанта (форма 1), фармацевтических составов, включающих указанную кристаллическую форму, применения в терапии и способов получения указанной кристаллической формы.
EA201071183A 2008-04-11 2009-04-09 Безводная кристаллическая форма малеата орвепитанта EA017082B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate
PCT/EP2009/054295 WO2009124996A1 (en) 2008-04-11 2009-04-09 Anhydrous crystal form of orvepitant maleate

Publications (2)

Publication Number Publication Date
EA201071183A1 true EA201071183A1 (ru) 2011-06-30
EA017082B1 EA017082B1 (ru) 2012-09-28

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071183A EA017082B1 (ru) 2008-04-11 2009-04-09 Безводная кристаллическая форма малеата орвепитанта

Country Status (27)

Country Link
US (1) US8309553B2 (ru)
EP (1) EP2297152B1 (ru)
JP (2) JP5875863B2 (ru)
KR (1) KR20110002090A (ru)
CN (1) CN102066376B (ru)
AR (1) AR071311A1 (ru)
AU (1) AU2009235440B2 (ru)
BR (1) BRPI0911678B8 (ru)
CA (1) CA2721119C (ru)
CL (1) CL2009000876A1 (ru)
CY (1) CY1115961T1 (ru)
DK (1) DK2297152T3 (ru)
EA (1) EA017082B1 (ru)
ES (1) ES2529295T3 (ru)
GB (1) GB0806652D0 (ru)
HR (1) HRP20141196T1 (ru)
IL (1) IL208597A0 (ru)
MX (1) MX2010011152A (ru)
PE (1) PE20091839A1 (ru)
PL (1) PL2297152T3 (ru)
PT (1) PT2297152E (ru)
RS (1) RS53732B1 (ru)
SI (1) SI2297152T1 (ru)
TW (1) TW201002714A (ru)
UY (1) UY31758A (ru)
WO (1) WO2009124996A1 (ru)
ZA (1) ZA201007120B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225001B1 (en) * 2007-10-30 2013-06-19 Elekta AB (PUBL) Radiotherapy apparatus
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
WO2014057003A1 (en) * 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses
DK3377064T3 (da) * 2016-01-08 2019-09-23 Nerre Therapeutics Ltd Orvepitant til behandling af kronisk hoste
CA3059418A1 (en) 2017-04-10 2018-10-18 Chase Therapeutics Corporation Nk1-antagonist combination and method for treating synucleinopathies
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
US20230190740A1 (en) 2020-04-03 2023-06-22 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CN115697332A (zh) 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
KR20090024140A (ko) 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
TWI456128B (zh) * 2007-11-02 2014-10-11 Entegris Inc 耦合裝置、流體感測器及可操作流體裝置
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
AU2009235440B2 (en) 2012-06-14
GB0806652D0 (en) 2008-05-14
EP2297152A1 (en) 2011-03-23
UY31758A (es) 2009-11-10
MX2010011152A (es) 2010-12-21
DK2297152T3 (da) 2015-01-26
AR071311A1 (es) 2010-06-09
ZA201007120B (en) 2011-11-30
BRPI0911678B8 (pt) 2021-05-25
TW201002714A (en) 2010-01-16
PE20091839A1 (es) 2010-01-07
PL2297152T3 (pl) 2015-04-30
IL208597A0 (en) 2010-12-30
PT2297152E (pt) 2015-02-16
CA2721119C (en) 2016-04-05
EA017082B1 (ru) 2012-09-28
AU2009235440A1 (en) 2009-10-15
CY1115961T1 (el) 2017-01-25
HRP20141196T1 (hr) 2015-02-13
KR20110002090A (ko) 2011-01-06
CL2009000876A1 (es) 2010-05-14
BRPI0911678B1 (pt) 2021-03-02
US8309553B2 (en) 2012-11-13
JP5875863B2 (ja) 2016-03-02
RS53732B1 (en) 2015-06-30
EP2297152B1 (en) 2014-11-12
WO2009124996A1 (en) 2009-10-15
CA2721119A1 (en) 2009-10-15
JP2014205688A (ja) 2014-10-30
CN102066376A (zh) 2011-05-18
CN102066376B (zh) 2014-01-01
ES2529295T3 (es) 2015-02-18
BRPI0911678A2 (pt) 2015-10-13
SI2297152T1 (sl) 2015-02-27
US20110166150A1 (en) 2011-07-07
JP2011516532A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
EA201100503A1 (ru) Глюкозидные производные и их применения
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY157661A (en) Bendamustine pharmaceutical compositions
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201100299A1 (ru) Органические соединения
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA201390381A1 (ru) Триазиноксадиазолы
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201201665A1 (ru) Новые соединения
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20090596L (no) Antivirale fosfinatforbindelser
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2013003034A (es) Lactamas piperidinilo-substituidas como moduladores de gpr119.
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA201171211A1 (ru) Производные оксадиазола

Legal Events

Date Code Title Description
RH4A Grant of a duplicate of a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment